Acute or subacute onset of cerebral demyelinating changes is considered to be multiple sclerosis, and patients often present with recurrent, multifocal symptoms of neurologic deficits in the form of visual impairment, limb weakness, sensory abnormalities, and ataxia. These symptoms are complex, and there are also neurologic signs that occur simultaneously, which must be treated super early. The goal of early treatment is to reduce the patient’s worsening symptoms, shorten the course of the disease, improve the degree of disability, and prevent complications. Early treatment involves the use of glucocorticoids as the first line of treatment for the acute phase of multiple sclerosis, which must be used in adequate doses to improve the symptoms of neurological deficits, and the principle of treatment is to use high doses and shorten the course of treatment. The most common reason for the chronic appearance of cerebral demyelination changes is due to chronic ischemia and hypoxia of the brain, which is related to cerebral arteriosclerosis. Patients usually need to strictly control the risk factors of cerebral arteriosclerosis, control high blood pressure, high blood fat, high blood sugar, reasonable diet.